Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Non-Current Assets: 2016-2025

Historic Other Non-Current Assets for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $515,000.

  • Rocket Pharmaceuticals' Other Non-Current Assets rose 2.39% to $515,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $515,000, marking a year-over-year increase of 2.39%. This contributed to the annual value of $529,000 for FY2024, which is 0.75% down from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Other Non-Current Assets is $515,000, which was down 0.00% from $515,000 recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Other Non-Current Assets peaked at $608,000 during Q4 2022, and registered a low of $455,000 during Q1 2021.
  • For the 3-year period, Rocket Pharmaceuticals' Other Non-Current Assets averaged around $515,091, with its median value being $515,000 (2025).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Other Non-Current Assets surged by 33.63% in 2022, and later declined by 12.34% in 2023.
  • Rocket Pharmaceuticals' Other Non-Current Assets (Quarterly) stood at $455,000 in 2021, then spiked by 33.63% to $608,000 in 2022, then dropped by 12.34% to $533,000 in 2023, then fell by 0.75% to $529,000 in 2024, then climbed by 2.39% to $515,000 in 2025.
  • Its last three reported values are $515,000 in Q3 2025, $515,000 for Q2 2025, and $514,000 during Q1 2025.